Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Schleinitz

Showing results (151-160 of 168) with videos related to

Pageof 17
Sort By:
Annals of Internal Medicine|July 28, 2025
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled TrialBenjamin Terrier, Grégory Pugnet, Claire de Moreuil, et al.
Journal of Neurology|May 16, 2025
Correction: Neurological manifestations in patients with VEXAS syndromeCharlotte Bert-Marcaz, Étienne Fortanier, Antoine Briantais, et al.
Journal of Neurology|February 1, 2025
Neurological manifestations in patients with VEXAS syndromeCharlotte Bert-Marcaz, Étienne Fortanier, Antoine Briantais, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registryBenjamin de Valence, Marion Delaune, Yann Nguyen, et al.
Human Vaccines & Immunotherapeutics|April 2, 2024
Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide surveyPierre-André Jarrot, Adrien Mirouse, Sébastien Ottaviani, et al.
Journal of Internal Medicine|November 24, 2025
Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profileValentine Pagis, Quentin Astouati, Lucas Pacoureau, et al.
The Lancet. Rheumatology|January 23, 2024
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational studyAnne Murarasu, Gaëlle Guettrot-Imbert, Véronique Le Guern, et al.
Journal of the American Academy of Dermatology|April 4, 2020
Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancyGrégoire Monseau, Océane Landon-Cardinal, Werner Stenzel, et al.
Cancer Cell|October 24, 2025
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionEli L Diamond, Jean-Francois Emile, Takeshi Fujino, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 7, 2023
Clinical and Prognostic Factors in Patients with IgG4-Related Kidney DiseaseAnis Chaba, Arnaud Devresse, Vincent Audard, et al.
Pageof 17

Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Annals of Internal Medicine|July 28, 2025
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled TrialBenjamin Terrier, Grégory Pugnet, Claire de Moreuil, et al.
Journal of Neurology|May 16, 2025
Correction: Neurological manifestations in patients with VEXAS syndromeCharlotte Bert-Marcaz, Étienne Fortanier, Antoine Briantais, et al.
Journal of Neurology|February 1, 2025
Neurological manifestations in patients with VEXAS syndromeCharlotte Bert-Marcaz, Étienne Fortanier, Antoine Briantais, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registryBenjamin de Valence, Marion Delaune, Yann Nguyen, et al.
Human Vaccines & Immunotherapeutics|April 2, 2024
Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide surveyPierre-André Jarrot, Adrien Mirouse, Sébastien Ottaviani, et al.
Journal of Internal Medicine|November 24, 2025
Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profileValentine Pagis, Quentin Astouati, Lucas Pacoureau, et al.
The Lancet. Rheumatology|January 23, 2024
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational studyAnne Murarasu, Gaëlle Guettrot-Imbert, Véronique Le Guern, et al.
Journal of the American Academy of Dermatology|April 4, 2020
Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancyGrégoire Monseau, Océane Landon-Cardinal, Werner Stenzel, et al.
Cancer Cell|October 24, 2025
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionEli L Diamond, Jean-Francois Emile, Takeshi Fujino, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 7, 2023
Clinical and Prognostic Factors in Patients with IgG4-Related Kidney DiseaseAnis Chaba, Arnaud Devresse, Vincent Audard, et al.
Pageof 17